Population-level adult mortality following the expansion of antiretroviral therapy in Rakai, Uganda.

Autor: Nabukalu D; Rakai Health Sciences Program., Reniers G; London School of Hygiene and Tropical Medicine.; University of the Witwatersrand., Risher KA; London School of Hygiene and Tropical Medicine., Blom S; London School of Hygiene and Tropical Medicine., Slaymaker E; London School of Hygiene and Tropical Medicine., Kabudula C; University of the Witwatersrand., Zaba B; London School of Hygiene and Tropical Medicine., Nalugoda F; Rakai Health Sciences Program., Kigozi G; Rakai Health Sciences Program., Makumbi F; Rakai Health Sciences Program.; Makerere University., Serwadda D; Rakai Health Sciences Program.; Makerere University., Reynolds SJ; National Institutes of Health.; Johns Hopkins Bloomberg School of Public Health., Marston M; London School of Hygiene and Tropical Medicine., Eaton JW; Imperial College London., Gray R; Rakai Health Sciences Program.; Johns Hopkins Bloomberg School of Public Health., Wawer M; Rakai Health Sciences Program.; Johns Hopkins Bloomberg School of Public Health., Sewankambo N; Rakai Health Sciences Program.; Makerere University., Lutalo T; Rakai Health Sciences Program.; Uganda Virus Research Institute.
Jazyk: angličtina
Zdroj: Population studies [Popul Stud (Camb)] 2020 Mar; Vol. 74 (1), pp. 93-102. Date of Electronic Publication: 2019 May 23.
DOI: 10.1080/00324728.2019.1595099
Abstrakt: There are limited data on the impact of antiretroviral therapy (ART) on population-level adult mortality in sub-Saharan Africa. We analysed data for 2000-14 from the Rakai Community Cohort Study (RCCS) in Uganda, where free ART was scaled up after 2004. Using non-parametric and parametric (Weibull) survival analysis, we estimated trends in average person-years lived between exact ages 15 and 50, per capita life-years lost to HIV, and the mortality hazards of people living with HIV (PLHIV). Between 2000 and 2014, average adult life-years lived before age 50 increased significantly, from 26.4 to 33.5 years for all women and from 28.6 to 33.8 years for all men. As of 2014, life-years lost to HIV had declined significantly, to 1.3 years among women and 0.4 years among men. Following the roll-out of ART, mortality reductions among PLHIV were initially larger in women than men, but this is no longer the case.
Databáze: MEDLINE